ArticleImmunotherapy2025

The value and safety of trilaciclib in combination with first-line chemotherapy and immunotherapy for extensive-stage SCLC.

Shuo He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.